X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (49) 49
elbasvir mk-8742 (44) 44
grazoprevir mk-5172 (39) 39
ribavirin (38) 38
hepatitis c virus (36) 36
humans (33) 33
treatment-naive (32) 32
hepatitis c (29) 29
mk-8742 (27) 27
hepatitis (26) 26
hepatitis-c virus (26) 26
genotype 1 infection (24) 24
pharmacology & pharmacy (24) 24
safety (24) 24
efficacy (23) 23
gastroenterology & hepatology (22) 22
antiviral agents - therapeutic use (21) 21
infectious diseases (20) 20
mk-5172 (20) 20
combination therapy (19) 19
elbasvir (19) 19
treatment-experienced patients (19) 19
hepacivirus - drug effects (18) 18
infections (18) 18
interferon (18) 18
hepatitis c, chronic - drug therapy (17) 17
male (17) 17
coinfection (16) 16
grazoprevir (15) 15
infection (15) 15
clinical trials (14) 14
label phase-2 trial (14) 14
antiviral agents (13) 13
genotypes (13) 13
hepatitis c - drug therapy (13) 13
human immunodeficiency virus--hiv (13) 13
open-label (13) 13
virus diseases (13) 13
adult (12) 12
female (12) 12
hcv ns5a inhibitor (12) 12
health aspects (12) 12
hepacivirus - genetics (12) 12
sofosbuvir (12) 12
cirrhosis (11) 11
hcv (11) 11
hiv infections - complications (11) 11
microbiology (11) 11
analysis (10) 10
antiviral agents - administration & dosage (10) 10
antiviral agents - adverse effects (10) 10
antiviral agents - pharmacology (10) 10
chemistry, medicinal (10) 10
genotype (10) 10
genotype & phenotype (10) 10
imidazoles - therapeutic use (10) 10
middle aged (10) 10
quinoxalines - therapeutic use (10) 10
viral nonstructural proteins - antagonists & inhibitors (10) 10
virology (10) 10
animals (9) 9
benzofurans - therapeutic use (9) 9
drug combinations (9) 9
drug therapy, combination (9) 9
hepatitis c, chronic - complications (9) 9
hiv (9) 9
inhibitor (9) 9
treatment outcome (9) 9
viruses (9) 9
drug therapy (8) 8
imidazoles - adverse effects (8) 8
liver cirrhosis (8) 8
ns3/4a protease (8) 8
plus ribavirin (8) 8
trial (8) 8
virus genotype 1 (8) 8
young adult (8) 8
aged (7) 7
antiretroviral drugs (7) 7
antiviral agents - chemistry (7) 7
antiviral agents - pharmacokinetics (7) 7
benzofurans - administration & dosage (7) 7
benzofurans - adverse effects (7) 7
benzofurans - pharmacokinetics (7) 7
care and treatment (7) 7
discovery (7) 7
hepatitis c, chronic - virology (7) 7
hepatology (7) 7
imidazoles - administration & dosage (7) 7
imidazoles - pharmacokinetics (7) 7
internal medicine (7) 7
medical research (7) 7
patients (7) 7
pharmacokinetics (7) 7
pharmacology (7) 7
quinoxalines - administration & dosage (7) 7
quinoxalines - adverse effects (7) 7
structure-activity relationship (7) 7
therapy (7) 7
treatment-naive patients (7) 7
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Antimicrobial Chemotherapy, ISSN 0305-7453, 03/2019, Volume 74, Issue 3, pp. 710 - 717
Abstract Background Elbasvir/grazoprevir is a once-daily fixed-dose combination therapy for the treatment of chronic HCV infection, including HCV/HIV... 
INFECTIOUS DISEASES | MK-8742 | HEPATITIS-C VIRUS | TRANSPORTERS | MK-5172 | COINFECTION | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | DISPOSITION
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2015, Volume 373, Issue 8, pp. 714 - 725
Journal Article
Annals of Internal Medicine, ISSN 0003-4819, 11/2016, Volume 165, Issue 9, pp. 625 - 634
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 05/2018, Volume 61, Issue 9, pp. 3984 - 4003
We describe the discovery of MK-6169, a potent and pan-genotype hepatitis C virus NS5A inhibitor with optimized activity against common resistance-associated... 
CORE | DOMAIN | CHEMISTRY, MEDICINAL | MK-8742 | PROTEIN | HCV NS5A | AMINAL DERIVATIVES | STANDARD | CARE | TETRACYCLIC-INDOLE CLASS
Journal Article
JOURNAL OF VIRAL HEPATITIS, ISSN 1352-0504, 05/2018, Volume 25, Issue 5, pp. 457 - 464
People with hepatitis C virus (HCV) infection other than genotype 1 represent a heterogeneous group. The aim of the phase 2 C-SCAPE study was to evaluate... 
clinical trial | INFECTIOUS DISEASES | PLUS RIBAVIRIN | ribavirin | MK-8742 | COMBINATION THERAPY | SOFOSBUVIR | MK-5172 | hepatitis | elbasvir | HCV INFECTION | TRIAL | TREATMENT-NAIVE | VIROLOGY | TREATMENT-EXPERIENCED PATIENTS | grazoprevir | INHIBITOR | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Antimicrobial Agents and Chemotherapy, ISSN 0066-4804, 11/2015, Volume 59, Issue 11, pp. 6922 - 6929
Elbasvir is an investigational NS5A inhibitor with in vitro activity against multiple HCV genotypes. Antiviral activity of elbasvir was measured in replicons... 
MK-8742 | EFFICACY | GRAZOPREVIR MK-5172 | SAFETY | COMBINATION THERAPY | RESISTANCE | ANTIVIRAL ACTIVITY | MICROBIOLOGY | PHARMACOLOGY & PHARMACY | INFECTION | PHASE-2 | RIBAVIRIN | Hepacivirus - drug effects | Humans | Middle Aged | Hepacivirus - genetics | Benzofurans - pharmacology | Genotype | Male | Imidazoles - pharmacology | Young Adult | Adolescent | Adult | Female | Replicon - genetics | Antiviral Agents
Journal Article
American Journal of Gastroenterology, ISSN 0002-9270, 06/2018, Volume 113, Issue 6, pp. 863 - 871
OBJECTIVES: Although direct-acting antiviral regimens have dramatically improved the treatment of hepatitis C virus (HCV) infection, there is some evidence... 
TREATMENT-NAIVE | EFFICACY | GRAZOPREVIR MK-5172 | SAFETY | COMBINATION THERAPY | TREATMENT-EXPERIENCED PATIENTS | GENOTYPE 1 INFECTION | ELBASVIR MK-8742 | RIBAVIRIN | GASTROENTEROLOGY & HEPATOLOGY | PEGINTERFERON | Clinical trials | Hepatitis | Infections | Interferon
Journal Article
Clinical Infectious Diseases, ISSN 1058-4838, 11/2016, Volume 63, Issue 10, pp. 1320 - 1324
Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 01/2017, Volume 60, Issue 1, pp. 290 - 306
Journal Article
CLINICAL INFECTIOUS DISEASES, ISSN 1058-4838, 02/2018, Volume 66, Issue 3, pp. 464 - 474
With the advent of the direct-acting antiviral agents (DAM) for chronic hepatitis C infection, the treatment paradigm has dramatically changed, especially the... 
INFECTIOUS DISEASES | VIRUS-INFECTION | GRAZOPREVIR MK-5172 | hepatitis C | MICROBIOLOGY | IMMUNOLOGY | HCV INFECTION | TREATMENT-NAIVE | directly acting agents | SOFOSBUVIR PLUS RIBAVIRIN | GENOTYPE 1 INFECTION | HCV | OPEN-LABEL TRIAL | ELBASVIR MK-8742 | ADVANCED LIVER-DISEASE | PHASE-2 TRIAL
Journal Article
JOURNAL OF VIRAL HEPATITIS, ISSN 1352-0504, 10/2017, Volume 24, Issue 10, pp. 895 - 899
Elbasvir (EBR; HCV NS5A inhibitor) and grazoprevir (GZR; HCV NS3/4A protease inhibitor) are approved as a fixed-dose combination to treat patients chronically... 
3 INFECTION | INFECTIOUS DISEASES | MK-8742 | SAFETY | SOFOSBUVIR | MK-5172 | RANDOMIZED-TRIAL | LABEL PHASE-2 TRIAL | COMBINATION | elbasvir | VIROLOGY | HEPATITIS-C VIRUS | TREATMENT-EXPERIENCED PATIENTS | hepatitis C virus | grazoprevir | genotype 3 | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article